A low dose of dasatinib reversed the expression levels of molecular markers of cardiomyopathy and reduced cardiac fibrosis in NS and LS mice. Low-dose dasatinib may represent a unifying therapy for the treatment of PTPN11-related cardiomyopathies. The gene discussed is PTPN11; the disease is cardiomyopathy.